Invention Grant
- Patent Title: VEGF antagonist formulations suitable for intravitreal administration
-
Application No.: US16582486Application Date: 2019-09-25
-
Publication No.: US11066458B2Publication Date: 2021-07-20
- Inventor: Eric Furfine , Daniel Dix , Kenneth Graham , Kelly Frye
- Applicant: REGENERON PHARMACEUTICALS, INC.
- Applicant Address: US NY Tarrytown
- Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee: REGENERON PHARMACEUTICALS, INC.
- Current Assignee Address: US NY Tarrytown
- Agency: Bozicevic, Field & Francis LLP
- Agent Karl Bozicevic
- Main IPC: A61K38/18
- IPC: A61K38/18 ; C07K14/71 ; C07K19/00 ; A61K9/00 ; A61K9/19 ; A61K38/17 ; C07K14/47 ; A61M5/178 ; A61K47/26 ; A61K47/02 ; A61K47/10
Abstract:
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
Public/Granted literature
- US20200017572A1 VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION Public/Granted day:2020-01-16
Information query
IPC分类:
